| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 84511 |
DOTA-Bn-FGK-Fab DOTA标记抗体片段 |
192 |
h |
2024-12-19 |
| 84512 |
cas:252554-78-2，Fmoc-Ala-Ser (Psi(Me,Me)pro)-OH，(4S)-3-[(2S)-2-[[(9H-芴-9-甲氧基)羰基]氨基]-1-氧代丙基]-2,2-二甲基-4-恶唑烷羧酸 |
155 |
kx |
2024-12-19 |
| 84513 |
DOTA-Nal3-Octreotide DOTANOC DOTA-Nal3-奥曲肽 |
159 |
h |
2024-12-19 |
| 84514 |
cas:2413428-36-9，MC-Gly-Gly-Phe-Gly，(S)-5-苄基-18-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)-4,7,10,13-四氧代-3,6,9,12-四氮杂十八烷-1-酸 |
154 |
kx |
2024-12-19 |
| 84515 |
MC-Val-Cit-PAB-PNP CAS:159857-81-5 |
250 |
zyl |
2024-12-19 |
| 84516 |
cas:2353409-52-4，Mal-amido-PEG8-Val-Gly-PAB-OH，马来酰亚胺-酰胺-八聚乙二醇-VAL-GLY-PAB-羟基 |
121 |
kx |
2024-12-19 |
| 84517 |
Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB CAS:2055042-69-6 |
135 |
zyl |
2024-12-19 |
| 84518 |
cas:1895916-22-9，MC-Val-Ala-OH， ADC试剂 |
149 |
kx |
2024-12-19 |
| 84519 |
cas:159857-70-2，MC-Val-Cit-Doxorubicin，MC-VAL-CIT-阿霉素 |
111 |
kx |
2024-12-19 |
| 84520 |
DOTA−Gal-NAPamide DOTA−Gal-纳帕胺 |
130 |
h |
2024-12-19 |
| 84521 |
DOTA-peptide-Lym-1 radioimmunotherapy DOTA-肽-Lym-1 |
154 |
h |
2024-12-19 |
| 84522 |
N-DBCO-N-bis(PEG2-amide-PEG4-Val-cit-PAB-MMAE)， N-二苯并环辛炔-N-双(二聚乙二醇-酰胺-四聚乙二醇-VAL-CIT-PAB-MMAE) |
165 |
kx |
2024-12-19 |
| 84523 |
DOTA-dGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 |
202 |
h |
2024-12-19 |
| 84524 |
DOTA-MGO DOTA-DGlu-(Glu)s-minigastrin |
139 |
h |
2024-12-19 |
| 84525 |
cas:2762518-86-3，NHS Ester-PEG4-Val-Cit-PAB-MMAE， ADC试剂 |
183 |
kx |
2024-12-19 |
| 84526 |
DOTA-scFv-anti-PSMA DOTA-scFv-抗PSMA脂质纳米粒(LNPs) |
197 |
h |
2024-12-19 |
| 84527 |
cas:2353409-45-5，BCN-PEG3-Val-Cit-PFP Ester， ADC试剂 |
157 |
kx |
2024-12-19 |
| 84528 |
cas:2112738-13-1，Mal-amido-PEG2-Val-Cit-PAB-PNP， ADC试剂 |
127 |
kx |
2024-12-19 |
| 84529 |
cas:2055041-39-7，Mal-PEG4-Val-Cit-PAB-OH， ADC试剂 |
181 |
kx |
2024-12-19 |
| 84530 |
cas:2055024-62-7，NH2-PEG3-Val-Cit-PAB-OH， ADC试剂 |
222 |
kx |
2024-12-19 |
| 84531 |
Fmoc-PEG3-Val-Cit，N-芴甲氧羰基-三聚乙二醇-VAL-CIT |
182 |
kx |
2024-12-19 |
| 84532 |
DOTA-anti-VLA-4 |
162 |
h |
2024-12-19 |
| 84533 |
DOTA-glycylglycylglycyl-l-p-isothiocyanatophenylalanine amide |
153 |
h |
2024-12-19 |
| 84534 |
CAS: 2748039-76-9， Alkyne-Val-Cit-PAB-FAM，炔-Val-Cit-PAB-FAM |
149 |
WYQ |
2024-12-19 |
| 84535 |
CAS:646502-53-6 MC-Val-Cit-PAB-MMAE的结构式 |
203 |
zyl |
2024-12-19 |
| 84536 |
Amino-PEG2-VG-N-Bis(PEG1-azide)，氨基-二聚乙二醇-VG-N-双（一聚乙二醇-叠氮） |
163 |
WYQ |
2024-12-19 |
| 84537 |
Azido-PEG8-Val-Cit-PAB-PNP，C34H47N9O12 |
147 |
WYQ |
2024-12-19 |
| 84538 |
化合物：TCO-MMAE，反式环辛烯-MMAE（其中MMAE为单甲基澳瑞他汀E的缩写） |
232 |
WYQ |
2024-12-19 |
| 84539 |
cas:2748039-77-0，Alkyne-Val-Cit-PAB-PNP，炔-VAL-CIT-PAB-PNP 酯 |
139 |
kx |
2024-12-19 |
| 84540 |
endo BCN-PEG3-Val-Cit，endo BCN-聚乙二醇3-缬氨酸-瓜氨酸，CAS号：1263166-91-1 |
200 |
WYQ |
2024-12-19 |
| 84541 |
cas:1803279-86-8，DBCO-C4-SulfoNHS ester， ADC试剂 |
128 |
kx |
2024-12-19 |
| 84542 |
Mal-PEG8-Val-Cit-PAB-MMAE CAS:2353409-69-3 |
180 |
zyl |
2024-12-19 |
| 84543 |
159857-80-4，MC-Val-Cit-PAB-OH，MC-VAL-CIT-PAB中间体 |
130 |
kx |
2024-12-19 |
| 84544 |
氨基-四聚乙二醇-Val-Cit-PAB-MMAE，Amino-PEG4-Val-Cit-PAB-MMAE，ADC定制 |
123 |
wyh |
2024-12-19 |
| 84545 |
CAS: 2748039-77-0，化合物：Alkyne-Val-Cit-PAB-PNP |
153 |
WYQ |
2024-12-19 |
| 84546 |
MAC glucuronide linker-2 CAS:229977-57-5 |
220 |
zyl |
2024-12-19 |
| 84547 |
DOTA-cPAM4 DOTA标记PAM4抗体 |
114 |
h |
2024-12-19 |
| 84548 |
PC SPDP-NHS carbonate ester， ADC试剂 |
231 |
kx |
2024-12-19 |
| 84549 |
Py-ds-Prp-OPFP的介绍 |
234 |
zyl |
2024-12-19 |
| 84550 |
cas:877864-04-5，THP-SS-alcohol， ADC试剂 |
130 |
kx |
2024-12-19 |
| 84551 |
MeO-DOTA−CC49 甲氧基DOTA偶联抗TAG-72单克隆抗体CC49 |
306 |
h |
2024-12-19 |
| 84552 |
Ala-Ala-Asn-PAB CAS:2149584-00-7 |
194 |
zyl |
2024-12-19 |
| 84553 |
cas:485800-27-9，Boc-NH-ethyl-SS-propionic acid， ADC试剂 |
172 |
kx |
2024-12-19 |
| 84554 |
cas:2228857-32-5，Azidoethyl-SS-propionic acid， ADC试剂 |
144 |
kx |
2024-12-19 |
| 84555 |
Fmoc-Val-Cit-PAB CAS:159858-22-7 |
223 |
zyl |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询